# Mytos Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mytos-bio

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.mytos.bio/
- Total disclosed funding: $19M
- Latest round: Series A (Nov 30, 2023)
- Investors on record: 3

## About

Founded in 2016 by its CEO, Ali Afshar, and co-founder, Ignacio Willats, and based in London, UK, Mytos Bio Limited, operates as a biotechnology company that offers a digital platform used for the automated manufacture of any human cell type. In November 2023, Mytos Bio Limited raised USD 19 million in Series A funding led by Buckley Ventures, with participation from IQ Capital and Wing VC.

Mytos offers various accelerated drug discovery solutions through the automation of laborious cell culture workflows. The company offers the Mytos Platform, which streamlines various cell culture processes in drug discovery and helps reduce costly contamination in cell cultures.

The platform automates multiple methods for generating neural progenitor cells (NPC), valuable for modelling neurodegenerative diseases.

The company plans to use the November 2023 funding to cope with the increasing demand by expediting the production and distribution of Mytos' automated cell production equipment to additional biotechnology and pharmaceutical organizations.

## Funding rounds

- Series A, Nov 30, 2023, $19M — IQ Capital, Wing, Buckley Ventures

## Investors

- IQ Capital (https://capitalatlas.ai/funds/iq-capital) — Series A
- Wing (https://capitalatlas.ai/funds/wing) — Series A
- Buckley Ventures (https://capitalatlas.ai/funds/buckley-ventures) — Series A